Benjamin F. Edwards & Company Inc. raised its position in Stryker Co. (NYSE:SYK) by 10.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,332 shares of the medical technology company’s stock after acquiring an additional 1,415 shares during the period. Benjamin F. Edwards & Company Inc.’s holdings in Stryker were worth $3,316,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Founders Capital Management LLC boosted its stake in Stryker by 3.9% in the second quarter. Founders Capital Management LLC now owns 10,887 shares of the medical technology company’s stock valued at $2,238,000 after acquiring an additional 411 shares in the last quarter. First Allied Advisory Services Inc. lifted its stake in shares of Stryker by 4.6% during the second quarter. First Allied Advisory Services Inc. now owns 17,939 shares of the medical technology company’s stock worth $3,688,000 after buying an additional 791 shares during the period. Commerce Bank lifted its stake in shares of Stryker by 2.4% during the second quarter. Commerce Bank now owns 39,890 shares of the medical technology company’s stock worth $8,201,000 after buying an additional 921 shares during the period. AGF Investments LLC acquired a new stake in shares of Stryker during the second quarter worth $1,366,000. Finally, Clarus Wealth Advisors lifted its stake in shares of Stryker by 19.3% during the second quarter. Clarus Wealth Advisors now owns 2,111 shares of the medical technology company’s stock worth $434,000 after buying an additional 342 shares during the period. Institutional investors own 73.13% of the company’s stock.

In other Stryker news, CEO Kevin Lobo sold 19,286 shares of Stryker stock in a transaction on Thursday, October 31st. The shares were sold at an average price of $215.71, for a total value of $4,160,183.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP M Kathryn Fink sold 28,690 shares of Stryker stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $220.97, for a total transaction of $6,339,629.30. The disclosure for this sale can be found here. Insiders have sold 67,524 shares of company stock valued at $14,731,927 over the last 90 days. 7.20% of the stock is currently owned by insiders.

NYSE SYK opened at $199.78 on Friday. The company has a market capitalization of $74.21 billion, a PE ratio of 27.33, a P/E/G ratio of 2.43 and a beta of 0.80. The company has a fifty day moving average of $213.13 and a 200 day moving average of $205.63. Stryker Co. has a 1 year low of $144.75 and a 1 year high of $223.45. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.18 and a quick ratio of 1.35.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.90 by $0.01. The company had revenue of $3.59 billion during the quarter, compared to the consensus estimate of $3.58 billion. Stryker had a net margin of 23.55% and a return on equity of 25.33%. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.69 earnings per share. Research analysts expect that Stryker Co. will post 8.23 earnings per share for the current year.

Several equities research analysts have recently commented on the stock. Morgan Stanley lifted their price objective on shares of Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 16th. BMO Capital Markets set a $216.00 price objective on shares of Stryker and gave the stock a “hold” rating in a research note on Friday, July 26th. Robert W. Baird lifted their price objective on shares of Stryker from $239.00 to $242.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Cantor Fitzgerald lifted their price objective on shares of Stryker from $190.00 to $230.00 and gave the stock a “neutral” rating in a research note on Friday, July 26th. Finally, Bank of America lifted their price objective on shares of Stryker from $220.00 to $245.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Six research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Stryker currently has a consensus rating of “Buy” and an average price target of $220.17.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Recommended Story: Short Selling Stocks, A Beginner’s Guide

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.